Perfluoroperhydrophenanthrene (Vitreon) in the management of giant retinal tears: results of a collaborative study

Ophthalmic Surg. 1993 Nov;24(11):759-63.

Abstract

Fifty cases of retinal detachment with a giant retinal tear were managed using perfluoroperhydrophenanthrene (Vitreon) as an intraoperative and postoperative tool. The giant tear was less than 180 degrees in 76% of the eyes, greater than 180 degrees in 22%, and greater than 270 degrees in 2%. Proliferative vitreoretinopathy was present in 40%. Vitreon was used only intraoperatively in 84% of the eyes, and was left in 16% for up to 4 weeks. Intraoperative retinal reattachment was achieved in 98%. Retinal attachment was maintained in 88%, with a mean follow up of 8.6 months. Postoperative visual acuity was better than 20/400 in 52%. Postoperative complications included cataract in 23%, choroidal effusion in 2%, hypotony in 4%, and recurrent retinal detachment with proliferative vitreoretinopathy in 26%.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Child
  • Eye Diseases / etiology
  • Female
  • Fluorocarbons*
  • Humans
  • Male
  • Middle Aged
  • Postoperative Complications
  • Recurrence
  • Retinal Detachment / surgery
  • Retinal Diseases / etiology
  • Retinal Perforations / surgery*
  • Visual Acuity
  • Vitreous Body

Substances

  • Fluorocarbons
  • perfluorophenanthrene